
Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2024
Description
Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2024
DelveInsight’s, “Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Neuromyelitis Optica Spectrum Disorder (NMOSD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Neuromyelitis Optica Spectrum Disorder (NMOSD): Overview
Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). The characteristic symptoms of NMOSD are either optic neuritis or myelitis, either of which may occur as the first symptom. Optic neuritis is an inflammation of the optic nerve leading to pain inside the eye which is rapidly followed by loss of clear vision (acuity). Usually, only one eye is affected (unilateral) although both eyes may be involved simultaneously (bilateral). Greater than 95% of patients with NMOSD report no relatives with the disease, but approximately 3% report having other relatives with the condition. There is a strong association with a personal or family history of autoimmunity, which are present in 50% of cases.
""Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neuromyelitis Optica Spectrum Disorder (NMOSD) pipeline landscape is provided which includes the disease overview and Neuromyelitis Optica Spectrum Disorder (NMOSD) treatment guidelines. The assessment part of the report embraces, in depth Neuromyelitis Optica Spectrum Disorder (NMOSD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neuromyelitis Optica Spectrum Disorder (NMOSD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Neuromyelitis Optica Spectrum Disorder (NMOSD) R&D. The therapies under development are focused on novel approaches to treat/improve Neuromyelitis Optica Spectrum Disorder (NMOSD).
This segment of the Neuromyelitis Optica Spectrum Disorder (NMOSD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Neuromyelitis Optica Spectrum Disorder (NMOSD) Emerging Drugs
- Telitacicept: RemeGen
- Ravulizumab: Alexion Pharmaceuticals
- SHR1459: Reistone Biopharma
- BAT4406F: Bio-Thera Solutions
- HBM9161: Harbour BioMed
- ARN-6039: Boston Pharmaceuticals
Further product details are provided in the report……..
Neuromyelitis Optica Spectrum Disorder (NMOSD): Therapeutic Assessment
This segment of the report provides insights about the different Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Oral
- Subcutaneous
- Molecule Type
- Immunoglobulin
- Monoclonal antibodies
- Protein
- Recombinant fusion proteins
- Small molecules
- Vaccine
- Product Type
Neuromyelitis Optica Spectrum Disorder (NMOSD): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neuromyelitis Optica Spectrum Disorder (NMOSD) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs.
Neuromyelitis Optica Spectrum Disorder (NMOSD) Report Insights
- Neuromyelitis Optica Spectrum Disorder (NMOSD) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs?
- How many Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neuromyelitis Optica Spectrum Disorder (NMOSD) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Neuromyelitis Optica Spectrum Disorder (NMOSD) and their status?
- What are the key designations that have been granted to the emerging drugs?
- RemeGen
- Alexion Pharmaceuticals
- Reistone Biopharma
- Nihon Pharmaceutical
- Harbour BioMed
- Bio-Thera Solutions
- Abide Therapeutics
- Bionure
- TG Therapeutics
- ENDECE
- Boston Pharmaceuticals
- NovelMed
- Telitacicept
- Ravulizumab
- SHR1459
- NPB-01
- HBM9161
- BAT4406F
- ABX-1431
- BN201
- Ublituximab
- NDC-1308
- ARN-6039
- NM8074
Table of Contents
50 Pages
- Introduction
- Executive Summary
- Neuromyelitis Optica Spectrum Disorder (NMOSD): Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
- Comparative Analysis
- Telitacicept: RemeGen
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- SHR1459: Reistone Biopharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- BAT4406F: Bio-Thera Solutions
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- ARN-6039: Boston Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Companies
- Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Products
- Neuromyelitis Optica Spectrum Disorder (NMOSD)- Unmet Needs
- Neuromyelitis Optica Spectrum Disorder (NMOSD)- Market Drivers and Barriers
- Neuromyelitis Optica Spectrum Disorder (NMOSD)- Future Perspectives and Conclusion
- Neuromyelitis Optica Spectrum Disorder (NMOSD) Analyst Views
- Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.